Eledon Pharmaceuticals announces R&D Day focused on tegoprubart's development in transplantation, featuring expert speakers and discussions.
Quiver AI Summary
Eledon Pharmaceuticals, Inc. will host an R&D Day in New York City on July 9, 2025, featuring insights from its executive team and key experts in transplantation. The event will focus on Eledon's lead investigational candidate, tegoprubart, highlighting its clinical development in organ and cell transplantation and the ongoing Phase 2 BESTOW trial. Discussions will also cover important topics like unmet needs in solid organ transplantation and clinical endpoints. The day will conclude with a Q&A session involving Eledon's management and experts. Interested individuals can register via email, and the event will be accessible through a live webcast on Eledon's website.
Potential Positives
- Eledon Pharmaceuticals is hosting an R&D Day featuring leading experts in transplantation, which enhances its visibility and credibility in the field.
- The event will present information on Eledon's lead investigational candidate, tegoprubart, highlighting its clinical development and ongoing Phase 2 BESTOW trial, indicating progress in their research efforts.
- Engagement with key opinion leaders during the live Q&A session presents an opportunity for networking and potentially gathering valuable insights for future development.
Potential Negatives
- Host of the R&D Day event and reliance on the success of its lead investigational candidate, tegoprubart, may indicate that the company lacks a diverse product pipeline.
- The press release does not provide any updates on the regulatory status or progress of tegoprubart in the Phase 2 BESTOW trial, raising concerns about potential delays or challenges.
- Highlighting unmet needs in solid organ transplantation may suggest that Eledon has yet to establish significant market presence or address existing competitive challenges effectively.
FAQ
What is the date and location of Eledon's R&D Day?
Eledon’s R&D Day will take place on July 9, 2025, in New York City.
Who are the experts speaking at the R&D Day?
Experts include Dr. Andrew Adams, Dr. John D. Cleveland, Dr. William E. Fitzsimmons, and Dr. Piotr Witkowski.
What is Eledon's lead investigational product?
Eledon’s lead investigational product is tegoprubart, an anti-CD40L antibody.
How can I register for the R&D Day event?
To register, please email [email protected].
Will the R&D Day be available online?
A live webcast and presentation materials will be available on Eledon's website.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ELDN Hedge Fund Activity
We have seen 35 institutional investors add shares of $ELDN stock to their portfolio, and 34 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC removed 2,364,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $9,739,680
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 1,316,623 shares (+489.4%) to their portfolio in Q1 2025, for an estimated $4,463,351
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 1,176,735 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $3,989,131
- POINT72 ASSET MANAGEMENT, L.P. removed 1,095,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $3,712,050
- MILLENNIUM MANAGEMENT LLC added 692,015 shares (+582.2%) to their portfolio in Q1 2025, for an estimated $2,345,930
- SIREN, L.L.C. added 690,170 shares (+inf%) to their portfolio in Q1 2025, for an estimated $2,339,676
- 22NW, LP added 636,364 shares (+inf%) to their portfolio in Q1 2025, for an estimated $2,157,273
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
IRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that it will host an R&D Day in New York City on Wednesday, July 9, 2025 beginning at 8:30 am ET.
The event will feature members of Eledon’s executive team and the following leading experts in transplantation:
- Andrew Adams, M.D., Ph.D., Professor of Surgery and Chief Division of Transplantation, John S. Najarian Surgical Chair in Clinical Transplantation, Department of Surgery, University of Minnesota; Executive Medical Director, Solid Organ Transplant Service Line, M Health Fairview
- John D. Cleveland, M.D., Associate Professor of Clinical Surgery, Program Director, Congenital Cardiac Surgery Fellowship, Children’s Hospital Los Angeles, Department of Surgery, Keck School of Medicine
- William E. Fitzsimmons, Pharm.D., M.S., Adjunct Professor, University of Illinois Colleges of Medicine and Pharmacy; Executive Committee, Transplant Therapeutics Consortium
- Piotr Witkowski, M.D., Ph.D., Professor of Surgery and Director of the Pancreatic and Islet Transplant Program at UChicago Medicine
The R&D Day event will highlight Eledon’s lead investigational candidate, tegoprubart, with a focus on its clinical development in organ and cell transplantation, including the ongoing Phase 2 BESTOW trial. Additional sessions will address unmet needs in solid organ transplantation, the evolution of clinical endpoints such as iBox and eGFR, and the Company’s strategic opportunities in islet cell transplantation and xenotransplantation. The program will conclude with a live Q&A session featuring Eledon’s management team and invited key opinion leaders.
To register for the in-person event, please email: [email protected] . A live webcast of the event and presentation materials will be available on the “Events” section of Eledon’s website at www.eledon.com .
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com .
Follow Eledon Pharmaceuticals on social media: LinkedIn ; Twitter
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
[email protected]
Media Contact:
Jenna Urban
CG Life
(212) 253 8881
[email protected]
Source: Eledon Pharmaceuticals
